United KingdomThe article discusses advancements in cancer therapy through the development of bispecific antibodies, which can target two different proteins simultaneously. These drugs have seen significant growth in clinical approval, increasing from 3 to over 20 approvals globally in just five years. Researchers are now exploring 'multispecific' antibodies that target three or more proteins, aiming to improve efficacy and reduce toxicity. While early versions faced challenges in production, recent improvements in technology and AI are enabling more sophisticated designs. Approved bispecific antibodies primarily function as 'T cell engagers,' bringing immune cells closer to cancer cells to enhance attacks. Despite progress, scientists continue to refine these therapies for better outcomes.
Bias read (Center): The article presents scientific developments in cancer treatment without overt ideological framing. It focuses on medical innovation, technological progress, and clinical trials, emphasizing objective data such as drug approvals, sales figures, and research milestones. There is no clear partisan sl抗
